Zacary P. Germon

New Lambton Heights
Newcastle, NSW, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Beyond base camp: PI3K/mTOR inhibition for the treatment of pediatric high-grade gliomas.

Beyond base camp: PI3K/mTOR inhibition for the treatment of pediatric high-grade gliomas.

Journal: Neuro-oncology

Published: February 02, 2026

The redox paradox in HGGs: ROS as drivers and destroyers.

The redox paradox in HGGs: ROS as drivers and destroyers.

Journal: Trends in cancer

Published: October 01, 2025

Beyond Base Camp: Promise and Pitfalls of PI3K/mTOR Inhibition in Pediatric High- Grade Gliomas.

Beyond Base Camp: Promise and Pitfalls of PI3K/mTOR Inhibition in Pediatric High- Grade Gliomas.

Journal: Research square

Published: May 19, 2025

Crosstalk between DNA methylation and hypoxia in acute myeloid leukaemia.

Crosstalk between DNA methylation and hypoxia in acute myeloid leukaemia.

Journal: Clinical epigenetics

Published: July 10, 2023

Correction to: Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection.

Correction to: Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection.

Journal: Clinical proteomics

Published: April 08, 2023

Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies.

Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies.

Journal: Science signaling

Published: March 28, 2023

ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma.

ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma.

Journal: Cancer research

Published: March 22, 2023

ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma.

ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma.

Journal: Cancer research

Published: March 22, 2023

PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma.

PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma.

Journal: The Journal of clinical investigation

Published: March 08, 2023

Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection.

Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection.

Journal: Clinical proteomics

Published: October 10, 2022

B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers.

B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers.

Journal: Molecular cancer research : MCR

Published: July 18, 2022

Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma.

Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma.

Journal: Neuro-oncology advances

Published: January 06, 2022

Showing 1-12 of 15

Last Updated: 09/26/2026